• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

成釉细胞癌治疗模式及预后因素对其结局的影响:一项对199例患者的系统评价和个体患者数据分析

Pattern of care and impact of prognostic factors in the outcome of ameloblastic carcinoma: a systematic review and individual patient data analysis of 199 cases.

作者信息

Giridhar Prashanth, Mallick Supriya, Upadhyay Ashish Datt, Rath Goura K

机构信息

Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi, India.

Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, India.

出版信息

Eur Arch Otorhinolaryngol. 2017 Oct;274(10):3803-3810. doi: 10.1007/s00405-017-4631-7. Epub 2017 Jun 9.

DOI:10.1007/s00405-017-4631-7
PMID:28600599
Abstract

Ameloblastic carcinoma is a rare locally aggressive odontogenic neoplasm. These tumors are most commonly found to arise from mandible. Because of rarity, there is limited information about the clinical behaviour of such patients. We intended to perform this review of published literature to assess the demographic profile, pattern of care and assess survival outcomes. Two authors independently searched PubMed, Google search, and Cochrane library for eligible studies from 1950 until July 1 2016 published in English language. Data of 199 patients were retrieved from 94 publications for statistical analysis. Median age of the entire cohort was 49 years (range 7-91 years). The analysis revealed that a clear twofold higher incidence in male with male-to-female ratio was 2.4:1 (140:57). Mandible was found to be the commonest tumor location in 66.7% (n = 132) cases followed by maxilla (31.8%) (n = 64). The present analysis revealed that median PFS of 57 months (95% CI 39-120 months) with 5- and 10-year PFS was found to be 47.88 and 29.48%, respectively. Median OS for the entire cohort which was 122 months (95% CI 96-153 months) with 2- and 5-year OS for the entire cohort was 87.16 and 69.08%, respectively. In univariate analysis, patients with an R0 resection were found to have a favourable survival. In addition, patients with localized disease and younger age were found to have a better survival. Adjuvant radiation did not confer any survival advantage. The present analysis revealed excellent outcome for patients treated with an R0 resection. Older patients with high-risk factor may benefit from adjuvant radiation. Role of chemotherapy needs to be evaluated.

摘要

成釉细胞癌是一种罕见的具有局部侵袭性的牙源性肿瘤。这些肿瘤最常见于下颌骨。由于其罕见性,关于此类患者临床行为的信息有限。我们旨在对已发表的文献进行综述,以评估人口统计学特征、治疗模式并评估生存结果。两位作者独立检索了PubMed、谷歌搜索和Cochrane图书馆,以查找1950年至2016年7月1日期间以英文发表的符合条件的研究。从94篇出版物中检索到199例患者的数据进行统计分析。整个队列的中位年龄为49岁(范围7 - 91岁)。分析显示男性发病率明显高出两倍,男女比例为2.4:1(140:57)。下颌骨是最常见的肿瘤部位,占66.7%(n = 132),其次是上颌骨(31.8%)(n = 64)。目前的分析显示,中位无进展生存期为57个月(95%可信区间39 - 120个月),5年和10年无进展生存率分别为47.88%和29.48%。整个队列的中位总生存期为122个月(95%可信区间96 - 153个月),整个队列的2年和5年总生存率分别为87.16%和69.08%。在单因素分析中,R0切除的患者生存率良好。此外,局限性疾病患者和年轻患者生存率更好。辅助放疗未带来任何生存优势。目前的分析显示,接受R0切除治疗的患者预后良好。有高危因素的老年患者可能从辅助放疗中获益。化疗的作用需要评估。

相似文献

1
Pattern of care and impact of prognostic factors in the outcome of ameloblastic carcinoma: a systematic review and individual patient data analysis of 199 cases.成釉细胞癌治疗模式及预后因素对其结局的影响:一项对199例患者的系统评价和个体患者数据分析
Eur Arch Otorhinolaryngol. 2017 Oct;274(10):3803-3810. doi: 10.1007/s00405-017-4631-7. Epub 2017 Jun 9.
2
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.卡莫司汀植入剂与替莫唑胺治疗新诊断的高级别胶质瘤的有效性和成本效益:一项系统评价与经济学评估
Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. doi: 10.3310/hta11450.
3
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
4
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
5
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
6
Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis.未治疗的霍奇金淋巴瘤患者化疗和放疗在第二原发性恶性肿瘤、总生存期和无进展生存期方面的优化:个体参与者数据分析
Cochrane Database Syst Rev. 2017 Sep 13;9(9):CD008814. doi: 10.1002/14651858.CD008814.pub2.
7
Patterns of care and impact of prognostic factors in the outcome of NUT midline carcinoma: a systematic review and individual patient data analysis of 119 cases.NUT中线癌治疗模式及预后因素对结局的影响:119例患者的系统评价与个体患者数据分析
Eur Arch Otorhinolaryngol. 2018 Mar;275(3):815-821. doi: 10.1007/s00405-018-4882-y. Epub 2018 Jan 22.
8
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.利用预后信息为乳腺癌患者选择辅助性全身治疗的成本效益
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.
9
Treatment options for progression or recurrence of glioblastoma: a network meta-analysis.治疗胶质母细胞瘤进展或复发的选择:网络荟萃分析。
Cochrane Database Syst Rev. 2021 May 4;5(1):CD013579. doi: 10.1002/14651858.CD013579.pub2.
10
Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer).纳武单抗用于成人霍奇金淋巴瘤(使用RobotReviewer软件进行的快速综述)
Cochrane Database Syst Rev. 2018 Jul 12;7(7):CD012556. doi: 10.1002/14651858.CD012556.pub2.

引用本文的文献

1
Ameloblastic Carcinoma: A 40-Year Scoping Review of the Literature.成釉细胞癌:40年文献综述
Curr Issues Mol Biol. 2025 Apr 8;47(4):261. doi: 10.3390/cimb47040261.
2
Metastasising ameloblastoma or ameloblastic carcinoma? A case report with mutation analyses.转移性腺瘤或造釉细胞瘤性癌?一例基因突变分析病例报告。
BMC Oral Health. 2023 Aug 12;23(1):563. doi: 10.1186/s12903-023-03259-6.
3
Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Odontogenic and Maxillofacial Bone Tumours.

本文引用的文献

1
Carbon ion therapy for ameloblastic carcinoma.碳离子治疗成釉细胞瘤。
Radiat Oncol. 2011 Feb 6;6:13. doi: 10.1186/1748-717X-6-13.
2
New classification of maxillary ameloblastic carcinoma based on an evidence-based literature review over the last 60 years.基于过去60年循证文献综述的上颌成釉细胞癌新分类。
Head Neck Oncol. 2009 Aug 12;1:31. doi: 10.1186/1758-3284-1-31.
3
Ameloblastic carcinoma: case report and literature review.成釉细胞癌:病例报告及文献综述
《头颈部肿瘤第五版世界卫生组织分类更新:牙源性和颌骨肿瘤》。
Head Neck Pathol. 2022 Mar;16(1):63-75. doi: 10.1007/s12105-021-01404-7. Epub 2022 Mar 21.
4
Innocuous presentation of ameloblastic carcinoma.成釉细胞瘤的无恶性表现。
BMJ Case Rep. 2021 Dec 14;14(12):e246907. doi: 10.1136/bcr-2021-246907.
5
Adenoid cystic carcinoma of the sublingual gland developing lung metastasis 20 years after primary treatment: A case report and literature review.舌下腺腺样囊性癌肺转移 20 年后:1 例报告及文献复习。
Medicine (Baltimore). 2021 Dec 10;100(49):e28098. doi: 10.1097/MD.0000000000028098.
6
Study on clinical and biological characteristics of ameloblastic carcinoma.研究成釉细胞瘤的临床和生物学特征。
Orphanet J Rare Dis. 2020 Nov 11;15(1):316. doi: 10.1186/s13023-020-01603-5.
7
Mandibular Setback as an Adjunctive Strategy for Reconstruction after Tumor Resection: A Technical Note and Case Report.下颌后缩作为肿瘤切除术后重建的辅助策略:技术说明与病例报告
Front Dent. 2019 Nov-Dec;16(6):473-477. doi: 10.18502/fid.v16i6.3447. Epub 2019 Dec 20.
8
Challenges in the diagnostics and treatment of ectopic ameloblastic carcinoma: a case report.异位成釉细胞癌的诊断与治疗挑战:一例报告
Croat Med J. 2020 Jul 5;61(3):271-275. doi: 10.3325/cmj.2020.61.271.
J Can Dent Assoc. 2003 Oct;69(9):573-6.
4
Ameloblastomas of the jaws.颌骨成釉细胞瘤
Oral Surg Oral Med Oral Pathol. 1955 Mar;8(3):281-97. doi: 10.1016/0030-4220(55)90350-9.
5
Ameloblastic carcinoma: report of an aggressive case with multiple bony metastases.成釉细胞癌:一例伴有多发骨转移的侵袭性病例报告。
Am J Otolaryngol. 2003 Jan-Feb;24(1):64-9. doi: 10.1053/ajot.2003.15.
6
Fine-needle aspiration cytology of ameloblastic carcinoma of the maxilla: a rare tumor.上颌骨成釉细胞癌的细针穿刺细胞学检查:一种罕见肿瘤。
Diagn Cytopathol. 1996 May;14(3):249-52. doi: 10.1002/(SICI)1097-0339(199604)14:3<249::AID-DC10>3.0.CO;2-L.
7
Ameloblastoma: biological profile of 3677 cases.成釉细胞瘤:3677例病例的生物学特征
Eur J Cancer B Oral Oncol. 1995 Mar;31B(2):86-99. doi: 10.1016/0964-1955(94)00037-5.
8
Ameloblastoma of the jaw. A reappraisal of the role of megavoltage irradiation.颌骨成釉细胞瘤。对兆伏放疗作用的重新评估。
Cancer. 1984 Feb 15;53(4):869-73. doi: 10.1002/1097-0142(19840215)53:4<869::aid-cncr2820530409>3.0.co;2-v.
9
Ameloblastic carcinoma: a clinicopathologic study and assessment of eight cases.成釉细胞癌:8例临床病理研究与评估
Oral Surg Oral Med Oral Pathol. 1987 Nov;64(5):570-6. doi: 10.1016/0030-4220(87)90063-6.
10
Radiotherapy in the treatment of ameloblastoma.放射治疗在成釉细胞瘤治疗中的应用。
Int J Oral Maxillofac Surg. 1988 Jun;17(3):201-5. doi: 10.1016/s0901-5027(88)80033-x.